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Context: Clues from the epidemiology of schizophre-
nia suggest that low levels of developmental vitamin D
may be associated with increased risk of schizophrenia.
Objective: To directly examine the association between
neonatal vitamin D status and risk of schizophrenia.
Design: Individually matched case-control study drawn
from a population-based cohort.
Setting: Danish national health registers and neonatal
biobank.
Participants: A total of 424 individuals with schizo-
phrenia and 424 controls matched for sex and date of
birth.
Main Outcome Measures: The concentration of 25
hydroxyvitamin D3 (25[OH]D3) was assessed from neo-
natal dried blood samples using a highly sensitive liquid
chromatography tandemmass spectroscopymethod. Rela-
tive risks were calculated for thematched pairs when ex-
amined for quintiles of 25(OH)D3.
Results: Compared with neonates in the fourth quin-
tile (with 25[OH]D3 concentrations between 40.5 and
50.9 nmol/L), those in each of the lower 3 quintiles
had a significantly increased risk of schizophrenia
(2-fold elevated risk). Unexpectedly, those in the
highest quintile also had a significantly increased risk
of schizophrenia. Based on this analysis , the
population-attributable fraction associated with neo-
natal vitamin D status was 44%. The relationship was
not explained by a wide range of potential confound-
ing or interacting variables.
Conclusions: Both low and high concentrations of neo-
natal vitamin D are associated with increased risk of
schizophrenia, and it is feasible that this exposure could
contribute to a sizeable proportion of cases in Denmark.
In light of the substantial public health implications of
this finding, there is an urgent need to further explore
the effect of vitamin D status on brain development and
later mental health.
Arch Gen Psychiatry. 2010;67(9):889-894
I N RECENT DECADES WE HAVElearned a great deal about the epi-demiology of schizophrenia.1Whilemany aspects remain to beclarified, several findings appear
relatively robust. One of the most consis-
tent features relates to season of birth—
people born in winter or spring have a
small but significantly increased risk of de-
veloping schizophrenia.2 The effect size of
this association increases with distance
from the equator.3,4 Of those with schizo-
phrenia, season of birth is also associated
with symptom profile (ie, summer birth
is associatedwithdeficit syndrome).5 There
is also robust evidence showing that the
offspring of somemigrant groups have in-
creased risk of schizophrenia.6,7 The effect
ismost prominent in thosewith dark skin7
such as Afro-Caribbean and African mi-
grants to England.8 Finally, there is ro-
bust evidence showing that, compared
with rural settings, individuals born and
raised in an urban setting are at increased
risk of schizophrenia.9 Because hypovita-
minosis D is more prevalent during win-
ter and early spring in dark-skinned mi-
grants living in cold climates and in urban
vs rural settings, these convergent clues led
to the hypothesis that developmental vi-
taminD deficiencymay be a risk factor for
schizophrenia.10 The ecological evidence
in support of this hypothesis has been sum-
marized elsewhere.4,10,11
The production of vitamin D3 depends
on the action of sunlight on the skin.12 Ul-
traviolet B radiation, acting on a choles-
terol metabolite in the epidermis, leads to
the production of vitamin D. Subsequent
hydroxylations in the liver to 25-
hydroxyvitaminD3 (25[OH]D3), and then
in the kidney, result in the active moiety
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1,25-dihydroxyvitaminD3 (1,25[OH]2D3), a potent seco-
steroidhormone.VitaminDproduction is strongly andcon-
sistently associated with the duration of the photoperiod
(which is influencedby latitude and season), and thepreva-
lence of hypovitaminosis D is particularly prominent in
dark-skinned people who live in cold climates.13,14
While profound deficiencies have been associatedwith
conditions such as rickets and osteomalacia, there is now
widespread recognition that hypovitaminosis Dmay con-
tribute to a broad range of adverse health outcomes13 in-
cluding neurological and neuropsychiatric disorders.15
Of particular interest to the hypothesis linking vitamin
D deficiency and schizophrenia, the enzyme required for
the production of 1,25(OH)D3 has now been identified
in the human brain,16 and there is evidence from rodent
models demonstrating that transient prenatal vitamin D
deficiency results in persistent changes in adult brain
structure, neurochemistry, and behavior.17-23
While the vitamin D hypothesis has received some in-
direct support from a Finnish birth cohort study,24 a small
pilot study25 that examined 25(OH)D3 in third-
trimestermaternal serawas inconclusive. Todate, no study
has directly examined the association between neonatal
vitamin D status and risk of schizophrenia. We had the
opportunity to examine this hypothesis in a large, popu-
lation-basedDanish case-control study.Wepredicted that
neonates with low concentrations of 25(OH)D3 would
be at increased risk of schizophrenia.
METHODS
PARTICIPANTS
The studywas based on record linkage between theDanish Psy-
chiatric Central Register26 and theDanishCivil Registration Sys-
tem27 as well as dried blood spots from the Newborn Screen-
ing Biobank.28 These dried blood spots have been systematically
stored for individuals born in Denmark sinceMay 1, 1981. The
Danish registers used in this study have near-complete cover-
age of the entire population, and register-derived diagnoses of
schizophrenia have good validity compared with research-
derived diagnoses.29We identified all singletons who had been
diagnosed with schizophrenia (International Statistical Classi-
fication of Diseases, 10th Revision [ICD-10] code F20) up to Sep-
tember 2005 and who were born in Denmark May 1, 1981, or
later. For each case we identified 1 control who was individu-
ally time-matched for sex, exact date of birth, birth in Den-
mark, and being alive with no history of schizophrenia on the
date of the first diagnosis of schizophrenia in thematched case.
The risk set included 923 cases and controls born between 1981
and 1994. From the risk set, we identified 430 case-control
matched pairs who had sufficient biological material to allow
at least 4 punches to be sampled (each disc is 3.2 mm in di-
ameter, which corresponds to 3.3 µL of whole blood). Of the
430 case-control pairs, the level of 25(OH)D3 was success-
fully measured in 424 pairs. This study was approved by the
Danish Data Protection Agency and the ethics committees of
Aarhus University and the University of Queensland.
ASSESSMENT OF VITAMIN D STATUS
For the main hypothesis, we examined 25(OH)D3 as the main
circulating form of vitamin D.13 In addition, we also measured
the related ergosterol-derived form, 25 hydroxyvitamin D2
(25[OH]D2),which can be obtained fromcertain dietary sources
(eg, mushrooms, fortified foods, vitamin supplements).
For each individual, one 3.2-mm disc of dried blood was
used. The assay method is highly sensitive and uses minimal
sample cleanup to reduce sample loss during extraction, chemi-
cal derivatization to enhance 25(OH)D2 and 25(OH)D3 ion-
ization, and liquid chromatography tandem mass spectros-
copy coupled with multiple reactant monitoring.30 Based on
samples fromAustralia andDenmark, we have previously dem-
onstrated that the assay can reliably detect seasonal (within-
year) fluctuations and is strongly correlated with neonatal cord
blood (r=0.86).31 Moreover, appropriate 25(OH)D3 concen-
trations can still be detected after prolonged storage time (eg,
greater than 20 years).30 The concentration of 25(OH)D3 is re-
ported in nmol/L and, as the protein-bound molecule is ex-
cluded from erythrocytes, results are reported as sera concen-
trations adjusted to account for the increased hematocrit in
capillary blood.
STATISTICAL ANALYSIS
To validate the assay, we first examined 25(OH)D3 for varia-
tion bymonth of birth (we predicted it would be lower inwinter/
spring vs summer/autumn) and in the offspring of immigrants
(we predicted it would be lower in the offspring of immigrants
vs the offspring of native-born individuals).
The main analyses were based on quintiles for 25(OH)D3
in the control sample, using conditional logistic regression.32
Owing to thematching scheme, thismeans that all relative risks
were controlled for sex, date of birth, and age. Based on pre-
vious research using the same psychiatric case register and based
on factors known to be associated with vitamin D status,13 we
included a range of variables as potential confounds in the analy-
ses. These includematernal, paternal, and sibling history ofmen-
tal illness subdividedhierarchically as schizophrenia (ICD-8 code
295; ICD-10 code F20), schizophrenialike psychoses (ICD-8
codes 297, 298.39, 301.83, and ICD-10 codes F21-F29), and
any other diagnoses (any ICD-8 or ICD-10 diagnosis), sex, age
at onset, year of birth, calendar year at onset, second-
generation immigrant status, degree of urbanization at place
of birth, maternal and paternal age at the time of the child’s
birth, gestational age, congenital malformations, Apgar score,
birth weight, and birth length.
Toexamine25(OH)D3as a continuousvariable,we alsoused
second-degree fractional polynomials to explore the relation-
ship between the variables of interest.33 If the exposure-risk re-
lationship was nonlinear, we planned further analyses to ex-
plore the nature of the relationship using more fine-grain
quantiles and individually assessing the list of variables previ-
ously included as covariates for interaction effects with
25(OH)D3. Population-attributable fractionwas calculated ac-
cording to the recommendations of Bruzzi et al34 (equation 10).
As described above, a relatively large proportion of caseswere
excluded owing to lack of the necessary amount of blood. Par-
ticipants born early in the study period were significantly less
likely to have sufficient biological material for inclusion in the
study (results not shown). However, as date of birth is amatch-
ing criterion in this study, this cannot bias our results. Fur-
thermore, to ensure that our sample was not subject to other
selection bias related to potential confounders (ie, parental his-
tory of mental illness, migrant status of parents, age of par-
ents, urbanization of place of birth), we systematically com-
pared the influence of these variables in the 424 case-control
pairs included in the study with the original risk set.We found
very similar magnitude and direction of all associations when
comparing these samples in separate analyses (results not
shown).
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RESULTS
In the entire sample, the distribution of 25(OH)D3 was
mildly skewed; the mean (SD) for all subjects was 35.9
(21.0) nmol/L (median, 32.3; interquartile range [IQR],
20.5-46.6). The dietary form of 25(OH)D2 was detected
above the lowest level of assay quantification in less than
5% of samples. The mean (SD) for all subjects was 10.0
(9.0) nmol/L (median, 7.4; IQR, 4.5-12.9). As pre-
dicted, 25(OH)D3 showed significant monthly varia-
tion (211=140.2; P .001) (Figure 1). Compared with
the offspring of native-born parents, the offspring of im-
migrants had significantly lower 25(OH)D3 levels (mean,
36.8; 95% confidence interval [CI], 35.3-38.4 vs mean,
29.3; 95% CI, 25.4-33.3; 22=12.1; P=.002).
The quintiles for 25(OH)D3 in the control groupwere
less than 19.7, 19.7 to 30.9, 31.0 to 40.4, 40.5 to 50.9, and
greater than 51 nmol/L. The distribution of 25(OH)D3 in
the cases and controls is shown in the eFigure (available
at http://www.archgenpsychiatry.com). Overall, the risk
of schizophreniawas significantly associatedwith the level
of 25(OH)D3 (24=12.6; P=.01). To best display the rela-
tionship between the variables of interests, neonates in the
fourth quintile were chosen as the reference category. The
relative riskwas significantly increased for neonates in each
of the 3 lowest quintiles of the distribution of 25(OH)D3.
Comparedwith the reference category, neonates in the low-
est quintile had a relative risk of 2.1 (95%CI, 1.3-3.5)while
those in the second and third quintiles had relative risks
of 2.0 (95% CI, 1.3-3.2) and 2.1 (95% CI, 1.3-3.4), re-
spectively. Unexpectedly, neonates in the highest quin-
tile of the distribution also had a significantly increased
relative risk of later developing schizophrenia when com-
paredwith the reference category (relative risk,1.71; 95%
CI, 1.04-2.8).
Figure 2 shows that the U-shaped nature of the ex-
posure-risk relationship was more prominent when the
data were assessed in deciles (based on the control
25[OH]D3 values). The gray line shows the best fit analy-
sis for the continuous data (a second-degree fractional
polynomial with orders 3 and 3). This polynomial had a
significantly better fit compared with both a straight line
(P=.046) and the null model (P=.003). This model pre-
dicted the lowest relative risk of schizophrenia in the 73rd
percentile (corresponding to 46.5 nmol/L of 25[OH]D3).
The U-shaped relationship between the level of 25
(OH)D3 and schizophrenia was not explained by inter-
action effects between 25(OH)D3 and awide range of vari-
ables (ie, sex, age at onset, year of birth, calendar year at
onset, second-generation immigrant status, degree of ur-
banization at place of birth, history of any mental illness
in a familymember,maternal and paternal age at the time
of the child’s birth, gestational age, congenital malfor-
mations, Apgar score, birth weight, and birth length [re-
sults not shown]).
With respect to the population-attributable fraction,
shifting all subjects to the optimal level (fourth quin-
tile) accounted for 43.6% of cases in this sample.
We have undertaken various post hoc analyses to fur-
ther explore the findings. We examined the exposure-
risk relationship when the fourth and fifth quintiles were
combined as the reference category (ie, 25[OH]D3 above
40.5 nmol/L). Those in the lowest and second quintiles
still had significantly increased risk of schizophrenia (OR,
1.7; 95% CI, 1.1-2.5 and OR, 1.8; 95% CI, 1.2-2.6, re-
spectively), while those in the third quintile did not have
a significantly increased risk (OR, 1.4; 95% CI, 0.9-2.0).
We went back to the original data for all samples above
40.5 nmol/L (the 2 upper quintiles). Keeping the tech-
nicians blind to case-control status, we checked all as-
pects of the tandem mass spectroscopy readout and
double-checked that the integration of the peak of in-
terest was correct. We examined several additional vari-
ables post hoc to explain the nonlinear relationship in-
cluding delays in collection of the sample (which could
have introduced a differential opportunity to access post-
natally derived 25[OH]D3 prior to sampling), admis-
sion to neonatal intensive care unit (which could have
altered properties such as the hematocrit or vitamin D
metabolism), and diagnosis of neonatal hyperbilirubi-
nemia (UV light, which is used as a treatment for this
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Figure 1. Mean level of 25 hydroxyvitamin D3 (25[OH]D3) by month of birth.
Vertical lines indicate 95% likelihood-based confidence intervals. Cases and
controls are combined. The level of 25(OH)D3 depended significantly on
month of birth (211=140.2; P .001).
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Figure 2. Relative risk (RR) of schizophrenia according to the level of
25(OH)D3, measured by the percentile of the distribution of 25(OH)D3
among the controls. Vertical lines indicate 95% confidence intervals (CI).
Children in the 70th to 80th percentile of the distribution were chosen as the
reference category for the categorical analyses. The gray line shows the fitted
second-degree fractional polynomial with orders 3 and 3.
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condition, may have resulted in higher vitamin D pro-
duction). None of these analyses could account for the
nonlinear exposure-risk relationship.
COMMENT
Neonatal vitaminD statuswas significantly associatedwith
the risk of schizophrenia. The nature of this relation-
ship was nonlinear. Compared with those in the fourth
quintile, those in lower quintiles had a 2-fold increased
risk of schizophrenia. Unexpectedly, we identified that
those in the highest quintile of 25(OH)D3 levels also had
a significantly increased risk of schizophrenia com-
pared with those in the fourth quintile.
J-shaped orU-shaped exposure-risk relationships have
been previously described in studies examining mater-
nal 25(OH)D3 status and neonatal growth outcomes35
as well as adult case-control studies exploring the rela-
tionship between 25(OH)D3 and cancer outcomes.36 Two
large studies that examined the association between vi-
tamin D status and cardiovascular disease37 and all-
causemortality38 both found nonlinear exposure-risk re-
lationships that were remarkably similar to the fractional
polynomial shown in Figure 2. In addition, there is in
vitro evidence that 1,25(OH)2D3 has a U-shaped rela-
tionshipwith a range of cellular responses including brain-
related outcomes such as the expression of L-type voltage-
sensitive calcium channels.39 In the current study,
however, the optimal range of neonatal vitamin D with
respect to later schizophrenia risk (ie, the fourth quin-
tile range, 40.5-50.9 nmol/L), appears somewhat low in
light of recent recommendations.40 While optimal neo-
natal 25(OH)D3 levels for brain-related outcomes have
yet to be defined, based on bone health, levels in the range
of 25-50 nmol/L have been defined as mild deficiency.40
We recommend caution in the interpretation of the
absolute levels of 25(OH)D3. The samples had been ar-
chived for 14 to 27 years, and it is likely that some deg-
radation of 25(OH)D3 occurs in the first few days after
collection and during storage.30 However, as date of birth
was a matching criterion in our study, there is no rea-
son to suspect that any degradation of 25(OH)D3 could
bias our results. The findings that neonatal 25(OH)D3
levels fluctuated across month of birth and were signifi-
cantly lower in the offspring of migrants lends addi-
tional weight to the validity of the assay.
It is also feasible that the nonlinear relationship iden-
tified in this study represents a summation of different
underlying exposure-risk relationships that reflect ge-
netic variation. Geneenvironment studies relating vi-
tamin D to cancer41 and bone outcomes42 suggest that
single-nucleotide polymorphisms in vitamin D–related
genes can influence the association between 25(OH)D3
and health outcomes.While speculative, it is feasible that
a subgroup of the population could have single-nucleo-
tide polymorphisms in genes that influence the conver-
sion of 25(OH)D3 to the active hormone 1,25(OH)2D3.
As a result, these individuals could have relatively high
levels of 25(OH)D3 (ie, the main circulating form used
in standard assays) but have lower levels of 1,25(OH)2D3.
In other words, the seemingly high levels in some indi-
viduals may be accompanied by a relative deficiency in
the biologically active form of vitamin D. We plan to
examine the interaction between neonatal 25(OH)D3,
single-nucleotide polymorphisms in candidate genes
related to vitamin D metabolism, and later schizophre-
nia in larger, adequately powered samples.
The nonlinear nature of the relationship between
neonatal 25(OH)D3 and risk of schizophrenia has
implications from a public health perspective. For
example, if we assume that future studies replicate the
nonlinear relationship and indicate that this relation-
ship is not a reflection of subgroups of the populations
who are particularly sensitive or resistant to vitamin D,
then different public health interventions would be
required for those with low vs high 25(OH)D3. We feel
it is premature to enter into these speculations based on
this study alone. The levels of 25(OH)D3 found in the
upper quintile of this study would not be generally
regarded as toxic or associated with detrimental health
outcomes.40 From a public health perspective, there is a
growing body of evidence showing that low prenatal
vitamin D is associated with adverse bone outcomes in
neonates and children.35,43 Developmental vitamin D
deficiency has also been proposed as a risk factor for
type I diabetes44 and multiple sclerosis.45 It is feasible
that different adverse health outcomes are associated
with different optimal ranges. Clearly, the field will
need more prospective studies to integrate the effect of
low developmental vitamin D on a diverse range of
childhood and adult outcomes.
There are several limitations to this study that war-
rant careful reflection. For example, the analysis based
on quintiles does not suggest a dose-response curve across
the lower 3 quintiles. While the fractional polynomial
curve and the analysis based ondeciles suggest that a dose-
response relationship may underlie this part of the ex-
posure-risk relationship, further scrutiny in studies based
on larger samples is required. Our sample is still rela-
tively young, and the relationship between neonatal vi-
tamin D and later-onset schizophrenia will require re-
visiting in future years. Concerning biological plausibility,
while there is good evidence showing that developmen-
tal vitaminDdeficiency is associatedwith changes in brain
development,15 there is a lack of data with respect to the
potential that 25(OH)D3 levels in the upper range found
in this study may also be associated with adverse brain
outcomes. Animal studies may be able to address these
issues.46
While this study was based on a candidate risk factor
that is parsimonious with respect to a diverse range of
epidemiological clues, and one that is biologically plau-
sible,15 we believe that the results from observational epi-
demiology should still be treated cautiously. The results
from evenwell-designed observational studies can be in-
fluenced by residual confounding.47 For example, there
may be a range of factors not considered by our study
that could independently influence schizophrenia risk but
also be associated with vitamin D status. For example,
low levels of 25(OH)D3may lead to increased risk of pre-
natal infection.48,49 Factors related to heat stress, mater-
nal fish intake, or maternal body mass index may also
warrant closer inspection in future studies.
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Schizophrenia is associated with a substantial bur-
den of disability. In the absence of major advances in the
efficacy of treatments, interventions that offer the pros-
pect of reducing the incidence of the disorder should be
pursued vigorously.1,50 It is acknowledged that there is
an urgent need to undertake more research that focuses
on the environmental risk factors and gene  environ-
mental associations with schizophrenia.51-53 Mindful of
these issues, we note that hypovitaminosis D is preva-
lent in many societies,13 and is a particular concern in
pregnant and lactating women.54 From a public health
perspective, the chance to prevent a serious disorder like
schizophrenia via simple, safe, and cheap nutritional
supplements is a scenario that has not previously seemed
plausible. Mindful of the caveats of estimates of popula-
tion-attributable fractions, there may be subgroups in
which vitamin D supplementation may be particularly
indicated. For example, in dark-skinned ethnic groups
living in cold countries, there is a substantially in-
creased risk of schizophrenia.7,55 Kirkbride and Jones56
have estimated that if the yet-to-be-identified risk fac-
tors underlying the increased risk of schizophrenia in
black minority ethnic groups living in England could be
identified and prevented, it may be feasible to reduce the
incidence of schizophrenia in this group by a staggering
87%. While there is much more work to be done, if fu-
ture studies confirm the association between develop-
mental vitamin D deficiency and risk of schizophrenia,
it raises the tantalizing prospect of the primary preven-
tion of this disabling group of brain disorders in a man-
ner comparable with folate supplementation and the pre-
vention of spina bifida.
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